Patents Assigned to Merck Patents GmbH
  • Process for the purification of a liquid-crystal mixture
    Patent number: 9737854
    Abstract: In a process for the purification of a liquid-crystal mixture (7), the liquid-crystal mixture (7) is passed through a first electrodialysis cell (2) and a concentrate solution (14) is passed through a second electrodialysis cell (8) which is adjacent to the first electrodialysis cell (2) and is separated by an ion-exchanger membrane (9), and an electric field transverse to a direction of passage of the liquid-crystal mixture (7) through the first electrodialysis cell (2) is generated with the aid of an anode/cathode arrangement (15, 16) arranged outside the electrodialysis cells (2, 8) so that ionized constituents of the liquid-crystal mixture (7) are discharged at the ion-exchanger membrane (9) and removed from the liquid-crystal mixture (7).
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: August 22, 2017
    Assignee: MERCK PATENT GMBH
    Inventor: Uwe Kaetzel
  • Materials for organic electroluminescence devices
    Patent number: 9738826
    Abstract: The present invention relates to copolymers containing indenocarbazole derivatives having electron- and hole-transporting properties, in particular for use in the interlayer, emission layer and/or charge-transport layer of electroluminescent devices. The invention furthermore relates to a process for the preparation of the compounds according to the invention and to electronic devices comprising these compounds.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: August 22, 2017
    Assignee: Merck Patent GmbH
    Inventors: Junyou Pan, Rémi Manouk Anémian, Susanne Heun, Thomas Eberle, Niels Schulte
  • Materials for organic electroluminescent devices
    Patent number: 9741942
    Abstract: The present invention relates to compounds according to formula (1), a method for producing these compounds and electronic devices, in particular organic electroluminescent devices containing said compounds.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: August 22, 2017
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Amir Hossain Parham, Christof Pflumm, Anja Jatsch, Thomas Eberle, Jonas Valentin Kroeber
  • LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME
    Publication number: 20170233652
    Abstract: The invention relates to a liquid-crystalline medium, preferably having a nematic phase and negative dielectric anisotropy, which comprises a) one or more compounds of formula I and b) one or more compounds selected from the group of compounds of the formulae II and III in which the parameters have the respective meanings indicated in claim 1, to the use thereof in an electro-optical display, particularly in an active-matrix display based on the VA, ECB, PALC, IPS or FFS effect, to displays of this type which contain a liquid-crystalline medium of this type, and to the use of the compounds of formula I for reduction of the dispersion of the birefringence of a liquid-crystalline medium which comprises one or more compounds of the formulae II and/or III.
    Type: Application
    Filed: July 13, 2015
    Publication date: August 17, 2017
    Applicant: Merck Patent GmbH
    Inventors: Atsutaka MANABE, Sven BARAN, Lars LIETZAU, Brigitte SCHULER
  • 3-aminocyclopentane carboxamide derivatives
    Patent number: 9732032
    Abstract: Compounds of the formula I in which R1, R4, R, X1, X2, X3, X4, q and W have the meanings indicated in Claim 1, are inhibitors of fatty acid synthase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: August 15, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Christos Tsaklakidis, Wolfgang Staehle, Brigitta Leuthner, Paul Czodrowski
  • Compounds for electronic devices
    Patent number: 9735371
    Abstract: The present invention relates to a compound of the formula (I), to the use of this compound in an electronic device, and to an electronic device comprising one or more compounds of the formula (I). The invention furthermore relates to the preparation of the compound of the formula (I) and to a formulation comprising one or more compounds of the formula (I).
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: August 15, 2017
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Arne Buesing, Frank Voges, Christof Pflumm, Amir Hossain Parham, Thomas Eberle, Teresa Mujica-Fernaud
  • General strategy for antibody library screening
    Patent number: 9733240
    Abstract: A generally applicable method for the selective covalent attachment of a reporter molecule to a replicating entity that allows one to obtain specific binders from a single round of library screening is disclosed. For example, selective biotinylation of phage particles and yeast cells displaying a binder to any given target can be achieved via application of a coupled enzyme reaction that includes a peroxidase, an oxidase and a catalase.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: August 15, 2017
    Assignee: Merck Patents GmbH
    Inventors: Stefan Becker, Tim Heiseler, Alexander Maass, Harald Kolmar
  • Arylquinazolines
    Patent number: 9732094
    Abstract: The invention relates to novel compounds of the formula (I) which can be used for the inhibition of serine-threonine protein kinases and for the sensitization of cancer cells to anticancer agents and/or ionizing radiation.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: August 15, 2017
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Ulrich Emde, Hans-Peter Buchstaller, Werner Mederski
  • Organic electroluminescence device
    Patent number: 9735385
    Abstract: The present invention relates to organic electroluminescent devices which comprise a mixture of at least two materials in the electron-transport layer.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: August 15, 2017
    Assignee: Merck Patent GmbH
    Inventors: Jonas Valentin Kroeber, Frank Voges, Susanne Heun, Joachim Kaiser
  • POLYMERISABLE MESOGENIC COMPOUND, LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY
    Publication number: 20170226422
    Abstract: The present invention relates to liquid crystal media comprising polymerisable mesogenic compounds with a bent shape, and to electro-optical displays comprising these media as light modulation media. In particular the electro-optical displays according to the present invention are displays, which are operated at a temperature, at which the liquid crystal modulation media are in an optically isotropic phase, preferably in a blue phase.
    Type: Application
    Filed: July 17, 2015
    Publication date: August 10, 2017
    Applicant: Merck Patent GmbH
    Inventors: Michael WITTEK, Norihiko TANAKA, Kevin ADLEM, Matthias BREMER, David WILKES, Ming-Chou WU
  • PYRROLIDINONE DERIVATIVES AS METAP-2 INHIBITORS
    Publication number: 20170226080
    Abstract: Compounds according to Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.
    Type: Application
    Filed: July 10, 2015
    Publication date: August 10, 2017
    Applicant: Merck Patent GmbH
    Inventors: Timo HEINRICH, Frank ZENKE, Felix ROHDICH, Manja FRIESE-HAMIM, Diane HAHN
  • ANTI-TNF ALPHA ANTIBODIES WITH PH-DEPENDEND ANTIGEN BINDING FOR IMPROVED TARGET CLEARENCE
    Publication number: 20170226199
    Abstract: The invention relates to anti-TNFa antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNFa antibody adalimumab (Humira®) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to adalimumab or biologically active variants or fragments thereof, wherein the CDR domains are modified by replacing one or more amino acid residues by histidine residues.
    Type: Application
    Filed: June 26, 2015
    Publication date: August 10, 2017
    Applicant: Merck Patent GmbH
    Inventors: Ralf GUENTHER, Stefan BECKER, Laura RHIEL, Bjoern HOCK, Christian SCHROETER
  • POLYMERISABLE LC MEDIUM AND POLYMER FILM WITH NEGATIVE OPTICAL DISPERSION
    Publication number: 20170226421
    Abstract: The invention relates to a polymerisable LC medium with negative optical dispersion, a polymer film with negative optical dispersion obtainable from such a medium, and the use of the polymerisable LC medium and polymer film in optical, electro optical, electronic, semiconducting or luminescent components or devices.
    Type: Application
    Filed: July 13, 2015
    Publication date: August 10, 2017
    Applicant: MERCK PATENT GMBH
    Inventors: Joseph SARGENT, Owain Llyr PARRI, Kevin ADLEM, Hassan ARASI
  • SAMPLE PREPARATION CONTAINER
    Publication number: 20170224860
    Abstract: A sample preparation container, preferably for use in sterility testing, comprising a housing (1) having a housing wall (2) defining an inside space (3), a support on which a membrane filter is placed or is to be placed so as to get in contact with a sampling fluid to be introduced into the inside space (3), and at least one inlet opening (4) to the inside space (3) and at least one outlet opening from the inside space (3). A sampling port (5) is provided for allowing access from the outside to the inside space (3), wherein said sampling port (5) is closed by a septum (6) and the septum (6) is separated from the inside space (3) by a barrier wall (7) which is preferably piercable or breakable on application of an external force, preferably applied through a sampling instrument like a needle (8).
    Type: Application
    Filed: September 16, 2015
    Publication date: August 10, 2017
    Applicant: Merck Patent GmbH
    Inventors: Gerard MULLER, Mathieu ARRAULT
  • Pyridopyrimidine derivatives as protein kinase inhibitors
    Patent number: 9725462
    Abstract: Compounds of the formula I in which R, R1 and R2 have the meanings indicated in claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and/or systemic lupus.
    Type: Grant
    Filed: July 10, 2013
    Date of Patent: August 8, 2017
    Assignee: Merck Patent GmbH
    Inventors: Lars Burgdorf, Daniel Kuhn, Tatjana Ross, Carl Deutsch
  • Polymer containing aldehyde groups, reaction and crosslinking of this polymer, crosslinked polymer, and electroluminescent device comprising this polymer
    Patent number: 9728724
    Abstract: The present invention relates to a polymer which comprises at least one structural unit which contains at least one aldehyde group, and to a process for the preparation of a crosslinkable or crosslinked polymer including a polymer which contains aldehyde groups. The present invention thus also relates to a crosslinkable polymer and a crosslinked polymer which is prepared by the process according to the invention, and to the use of this crosslinked polymer in electronic devices, in particular in organic electroluminescent devices, so-called OLEDs (OLED=organic light emitting device).
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: August 8, 2017
    Assignee: Merck Patent GmbH
    Inventors: Aurélie Ludemann, Rémi M. Anémian, Alice Julliart
  • Liquid-crystal displays and liquid-crystalline media having homeotropic alignment
    Patent number: 9726933
    Abstract: The present invention relates to liquid-crystalline media (LC media) having negative or positive dielectric anisotropy comprising self-alignment additives (SAMs) with an at least one bifunctional or polyfunctional anchor group, which effects the homeotropic (vertical) alignment of the LC media at a surface or the cell walls of a liquid-crystal display (LC display). The invention therefore also encompasses LC displays having homeotropic alignment of the liquid-crystalline medium (LC medium) without conventional imide alignment layers. The LC media may be supplemented by a polymerizable or polymerized component, which serves for stabilization of the alignment, for adjustment of the tilt angle and/or as passivation layer.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: August 8, 2017
    Assignee: Merck Patent GmbH
    Inventors: Graziano Archetti, Andreas Taugerbeck, Renate Bender, Rocco Fortte, Peer Kirsch, Izumi Saito
  • 7-azaindole derivatives
    Patent number: 9725446
    Abstract: Compounds of the formula (I) in which R, R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumors.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: August 8, 2017
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Christian Sirrenberg, Thomas J. J. Mueller, Eugen Merkul, Gnuni Amatunu Karapetyan
  • FGF-18 compound dosing regimen
    Patent number: 9724388
    Abstract: The present invention provides a new dosing regimen for administration of FGF-18 in the treatment of a cartilage disorder, such as osteoarthritis or cartilage injury. Specifically provided is a preferred treatment scheme comprising administration every 2 weeks of an FGF-18 compound per treatment cycle. The new dosing regimen can include the co-administration of a anti-inflammatory drug.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: August 8, 2017
    Assignee: MERCK PATENT GMBH
    Inventors: Christoph H. Ladel, Hans Guehring
  • ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20170218070
    Abstract: The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.
    Type: Application
    Filed: January 9, 2017
    Publication date: August 3, 2017
    Applicant: Merck Patent GmbH
    Inventors: Axel Hoffmann, Heinrich Lannert, Klaus Brischwein, Frederic Christian Pipp, Juergen Reindl, Karin Groll, Michael Zuehlsdorf, Otmar Pfaff, Sabine Raab, Ulrike Dau, Benoit Destenaves